December 3, 2024 03:23 PM EST
R&D
Pharma

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Kyle LaHucik

Senior Reporter

GSK has axed a Phase 2 study of a chron­ic he­pati­tis B ther­a­peu­tic vac­cine, adding to a string of treat­ment R&D hur­dles for the liv­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Ap­plied Ther­a­peu­tics gets FDA warn­ing let­ter over study of re­ject­ed rare dis­ease drug

A service from the Financial Times